APC. Advanced Proteome Therapeutics

Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma

Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma

VANCOUVER, British Columbia , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma.

Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens to fight cancer. The combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology, featuring the mushroom toxin amanitin, has led to conjugates that possess high target-specific anti-cancer potency established in several human cancer cell types.

The Company is pleased to announce that the lead ADC has now impressively demonstrated complete tumor regression at a single low dose in two challenging mouse models of human cancer (JIMT-1, NCI-N87) over extended observation periods with clear superiority over benchmark molecules used as positive controls. The potency and efficacy exhibited by the ADC is profound and the studies are still ongoing, as the improved condition of the test animals permitted a longer-term evaluation than originally contemplated.

Dr. Allen Krantz, CSO and Founder of APC commented “These exciting results have exceeded our high expectations. APC’s ability to rapidly generate superior antibody-drug conjugates without having to perform labor-intensive engineering of the antibody to enable the point of selective attachment of the drug, represents a game changing advantage for our Company in the field of ADCs.  Our site selective approach of linking drugs to a favored and universally present site in therapeutically-important antibodies is a powerful and efficient way of producing homogeneous cancer killing ADCs with excellent biophysical properties. The validation of our technology now opens the door to advanced state-of-the-art therapeutic approaches, which are in progress, and for which we have recently filed key patents.”

APC and Heidelberg Pharma have agreed to extend their collaboration in two important ways. Heidelberg Pharma are in the process of negotiating terms for APC’s linker technology to be included in the amanitin tool box available to pharma partners developing new ADCs. Also, Heidelberg Pharma and APC will continue to identify and test ADC drug candidates that best exploit the combined strengths of both our technologies.

Dr. Andreas Pahl, CSO of Heidelberg Pharma, said “APC’s linker technology, which does not require any modification of the natural framework of an antibody prior to its conversion into a drug, can significantly streamline development of a new generation of ADCs from existing, well proven antibodies.”

Bill Dickie, President and CEO of APC added “We are pleased to extend our collaboration with Heidelberg Pharma’s innovative technology and outstanding team, as we work together to advance the field of ADCs and build value for our companies.”

ABOUT THE COMPANY:

Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells.  This type of agent is capable of greater potency, higher specificity and lower toxicity than other therapies that can also attack healthy cells.  The Company is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Corporation

Bill Dickie

President and CEO

Tel: 617 358-9777

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

EN
14/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Advanced Proteome Therapeutics

 PRESS RELEASE

Advanced Proteome Therapeutics Reports Positive Results and Advances C...

Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma VANCOUVER, British Columbia , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens to fight cancer. The combination of APC's proprietary site-selective pro...

 PRESS RELEASE

Advanced Proteome Therapeutics Reports Progress on Collaboration with ...

Advanced Proteome Therapeutics Reports Progress on Collaboration with Noria Pharmaceuticals VANCOUVER, British Columbia, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce the successful completion of the first phase of the Collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing and dynamic field of antibody radioisotope conjugates which is expected to have a major impact in the fight against cancer. APC has succeeded in creating a construct using its proprietary, site-se...

 PRESS RELEASE

APC Comments on Favorable Results in Initial Animal Studies

APC Comments on Favorable Results in Initial Animal Studies VANCOUVER, British Columbia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report favorable results in initial animal studies. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens. The combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology, featuring the mushroo...

 PRESS RELEASE

Advanced Proteome Therapeutics Announces Progress on Antibody-Radioiso...

Advanced Proteome Therapeutics Announces Progress on Antibody-Radioisotope Conjugate Initiative VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report significant progress in applying the Company’s site-selective linker technology to advance the rapidly growing field of antibody-radioisotope conjugates. APC has initiated a program to create well-defined, chemically controlled constructs that are expected to display higher selectivity and efficiency than has previously...

 PRESS RELEASE

Advanced Proteome Therapeutics Provides Overview of Current Activities...

Advanced Proteome Therapeutics Provides Overview of Current Activities and Strategic Objectives VANCOUVER, British Columbia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to provide an overview of current projects prior to more detailed news releases that will be disclosed shortly. Radioimmunoconjugates APC’s site-selective technology is being employed in the emergent field of radioimmunoconjugates (radioactive substances that can carry radiation directly to cancer cells.) These conjugates are ma...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch